Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 14/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6604045 | 1.00 | TACR1 (0.44) | TACR1HCRTR2CFTRCYP2D6KDM1A | |
| SCHEMBL6607867 | 0.97 | TACR1 (0.44) | TACR1HCRTR2CFTRCYP2D6KDM1A | |
| SCHEMBL8664244 | 0.92 | TACR1 (0.45) | TACR1HCRTR2CFTRCYP2D6KDM1A | |
| SCHEMBL6606866 | 0.92 | TACR1 (0.45) | TACR1HCRTR2CFTRCYP2D6KDM1A | |
| SCHEMBL6606522 | 0.87 | TACR1 (0.44) | TACR1HCRTR2CFTRCYP2D6KDM1A | |
| SCHEMBL7030644 | 0.87 | TACR1 (0.44) | TACR1HCRTR2CFTRCYP2D6KDM1A | |
| SCHEMBL7032701 | 0.86 | TACR1 (0.46) | TACR1HCRTR2CFTRCYP2D6KDM1A | |
| SCHEMBL6604119 | 0.86 | TACR1 (0.46) | TACR1HCRTR2CFTRCYP2D6KDM1A | |
| SCHEMBL6608982 | 0.84 | TACR1 (0.44) | TACR1HCRTR2CFTRCYP2D6KDM1A | |
| SCHEMBL7026966 | 0.84 | TACR1 (0.44) | TACR1HCRTR2CFTRCYP2D6KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105124-A1 | Substituted benzolactam compounds | SOBOLOV-JAYNES SUSAN BETH (US) | 2003-06-05 | — | — | US | disclosed |
| US-20020052503-A1 | Substituted benzolactam compounds as substance p antagonists | WAKABAYASHI HIROAKI (JP) | 2002-05-02 | — | — | US | disclosed |
| US-6288225-B1 | Substituted benzolactam compounds as substance P antagonists | PFIZER INC | 2001-09-11 | — | — | US | disclosed |
| EP-0840732-B1 | SUBSTITUTED BENZOLACTAM COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6180647-B1 | GASTROINTESTINAL DISORDERS; NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2001-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105124-A1 | Substituted benzolactam compounds | NPY1R, HAX1, CBR1 | TACR1 687/4885HCRTR2 143/4885CFTR 105/4885 |
| US-20020052503-A1 | Substituted benzolactam compounds as substance p antagonists | NPY1R, OPRM1, OPRL1 | TACR1 4/4885HCRTR2 135/4885CFTR 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.